The addition of dual immunotherapy with ipilimumab (Yervoy) and nivolumab (Opdivo) to percutaneous liver perfusion significantly reduced the risk of disease progression or death in patients with metastatic uveal melanoma. This combination treatment delays the progression of a single form of melanoma that typically spreads to the liver. The study demonstrated that adding dual checkpoint inhibitors to liver perfusion confers this benefit. Uveal melanoma is a specific type in which the liver is a common site of metastasis. Treatment includes percutaneous liver perfusion along with immunotherapy. These findings confirm the effectiveness of the combined approach in delaying disease progression.